Display options
Cite
Meijer AJM, Diepstraten FA, Langer T, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64doi: 10.1038/s41698-021-00178-z.
Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J. E., van der Kooi, A. L. F., Kremer, L. C. M., Kruseova, J., Pluijm, S. M. F., Kuehni, C. E., van der Pal, H. J. H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J. C. M. M., Rassekh, S. R., Wright, G. E. B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J. D., Bhavsar, A. P., Am Zehnhoff-Dinnesen, A. G., Carleton, B. C., Zolk, O., van den Heuvel-Eibrink, M. M. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), 64. https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, et al. "TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study." NPJ precision oncology vol. 5,1 (2021): 64. doi: https://doi.org/10.1038/s41698-021-00178-z
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. PMID: 34262104; PMCID: PMC8280110.
Copy Download .nbib Format: NLM
Share it on

NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.

TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

NPJ precision oncology

A J M Meijer, F A Diepstraten, T Langer, L Broer, I K Domingo, E Clemens, A G Uitterlinden, A C H de Vries, M van Grotel, W P Vermeij, R A Ozinga, H Binder, J Byrne, E van Dulmen-den Broeder, M L Garrè, D Grabow, P Kaatsch, M Kaiser, L Kenborg, J F Winther, C Rechnitzer, H Hasle, T Kepak, K Kepakova, W J E Tissing, A L F van der Kooi, L C M Kremer, J Kruseova, S M F Pluijm, C E Kuehni, H J H van der Pal, R Parfitt, C Spix, A Tillmanns, D Deuster, P Matulat, G Calaminus, A E Hoetink, S Elsner, J Gebauer, R Haupt, H Lackner, C Blattmann, S J C M M Neggers, S R Rassekh, G E B Wright, B Brooks, A P Nagtegaal, B I Drögemöller, C J D Ross, A P Bhavsar, A G Am Zehnhoff-Dinnesen, B C Carleton, O Zolk, M M van den Heuvel-Eibrink,

Affiliations

  1. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. [email protected].
  2. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  3. Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
  4. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  5. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
  6. Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  7. Oncode Institute, Utrecht, The Netherlands.
  8. German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  9. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
  10. Boyne Research Institute, Drogheda, Ireland.
  11. VU Medical Center, Amsterdam, The Netherlands.
  12. Department of Neurooncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  13. Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
  14. Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark.
  15. Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  16. Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
  17. University Hospital Brno, Brno, Czech Republic.
  18. International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
  19. Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  20. Department of Obstetrics and Gynecology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  21. Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.
  22. Department of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
  23. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  24. Pediatric Hematology and Oncology, University Children's Hospital Bern, University of Bern, Bern, Switzerland.
  25. Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
  26. Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
  27. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Utrecht, Utrecht, The Netherlands.
  28. Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
  29. Department of Internal Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  30. Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  31. Department of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria.
  32. Department of Pediatric Oncology/Hematology/Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
  33. BC Children's Hospital Research Institute, Vancouver, BC, Canada.
  34. Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
  35. Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, BC, Canada.
  36. Departement of Otorhinolaryngology, Erasmus Medical Center, Rotterdam, The Netherlands.
  37. Faculty of Pharmaceutical Sciences, University of British Columbia, British Columbia, Canada.
  38. Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
  39. Institute of Clinical Pharmacology, Brandenburg Medical School, Rüdersdorf, Germany.

PMID: 34262104 PMCID: PMC8280110 DOI: 10.1038/s41698-021-00178-z

Abstract

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10

© 2021. The Author(s).

References

  1. J Clin Oncol. 2016 Apr 10;34(11):1248-55 - PubMed
  2. Database (Oxford). 2015 Jul 24;2015:bav071 - PubMed
  3. Eur J Cancer. 2018 Nov;103:238-248 - PubMed
  4. Mol Med Rep. 2014 Feb;9(2):725-9 - PubMed
  5. Nat Commun. 2017 Nov 28;8(1):1826 - PubMed
  6. Nat Commun. 2014 Jun 13;5:3934 - PubMed
  7. BMC Res Notes. 2014 Dec 11;7:901 - PubMed
  8. PLoS Genet. 2006 Dec;2(12):e190 - PubMed
  9. Stem Cell Reports. 2013 Dec 26;2(1):36-43 - PubMed
  10. J Clin Oncol. 2005 Dec 1;23(34):8588-96 - PubMed
  11. Pediatr Hematol Oncol. 2017 Mar;34(2):120-129 - PubMed
  12. Tumour Biol. 2012 Apr;33(2):363-72 - PubMed
  13. BMC Med Genet. 2014 Feb 06;15:18 - PubMed
  14. J Neurosci. 2015 Apr 22;35(16):6366-80 - PubMed
  15. J Clin Oncol. 2014 Feb 20;32(6):527-34 - PubMed
  16. Nat Genet. 2012 Jul 22;44(8):955-9 - PubMed
  17. Pharmacogenomics J. 2009 Feb;9(1):23-33 - PubMed
  18. Sci Rep. 2019 Oct 23;9(1):15192 - PubMed
  19. HNO. 2007 Apr;55(4):299-306 - PubMed
  20. Pharmacogenomics. 2011 Jul;12(7):1039-50 - PubMed
  21. Eur J Cancer. 2004 Nov;40(16):2445-51 - PubMed
  22. Nat Commun. 2019 Jan 18;10(1):309 - PubMed
  23. Cancer Treat Rev. 2010 Jun;36(4):277-85 - PubMed
  24. Blood. 2013 Jun 27;121(26):5145-53 - PubMed
  25. N Engl J Med. 2006 Oct 12;355(15):1572-82 - PubMed
  26. JMIR Res Protoc. 2019 Mar 19;8(3):e11868 - PubMed
  27. Front Cell Neurosci. 2017 Oct 27;11:338 - PubMed
  28. Lancet Oncol. 2019 Jan;20(1):e29-e41 - PubMed
  29. Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):713-21 - PubMed
  30. Int J Mol Med. 2013 May;31(5):1255-61 - PubMed
  31. Nat Genet. 2006 Aug;38(8):904-9 - PubMed

Publication Types